Zhejiang Jolly Pharmaceutical (300181) Fundamentals 2026 — P/E 15.3x, Revenue Analysis | SniperIQ
Zhejiang Jolly Pharmaceutical (300181) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥9.9B, trading at ¥14.35 on the SHZ. This SniperIQ fundamentals page covers Zhejiang Jolly Pharmaceutical's valuation (P/E 15.3x, P/B 2.9x), profitability (net margin 20.9%), revenue (¥3.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zhejiang Jolly Pharmaceutical's market cap?
Zhejiang Jolly Pharmaceutical (300181) has a market capitalization of approximately ¥9.9B, trading at ¥14.35 on the SHZ. Market cap moves with the live share price.
What is Zhejiang Jolly Pharmaceutical's P/E ratio?
Zhejiang Jolly Pharmaceutical's trailing twelve-month P/E ratio is 15.3x, with a price-to-book (P/B) of 2.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zhejiang Jolly Pharmaceutical?
Zhejiang Jolly Pharmaceutical runs a net profit margin of 20.9%, a gross margin of 62.3%, and an operating margin of 24.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zhejiang Jolly Pharmaceutical generate?
Zhejiang Jolly Pharmaceutical reported revenue of ¥3.0B for fiscal year 2025, with net income of ¥632M and earnings per share (EPS) of 0.92. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zhejiang Jolly Pharmaceutical pay a dividend?
Zhejiang Jolly Pharmaceutical offers a trailing dividend yield of about 2.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Zhejiang Jolly Pharmaceutical financially healthy?
Zhejiang Jolly Pharmaceutical carries a debt-to-equity ratio of 0.22x and a current ratio of 1.55x, with a market beta of 0.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zhejiang Jolly Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zhejiang Jolly Pharmaceutical (300181) the key facts are: market cap ¥9.9B, P/E 15.3x, revenue ¥3.0B, 52-week range 12.3-21.07. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zhejiang Jolly Pharmaceutical's full fundamentals live
Get Zhejiang Jolly Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.